Medical Condition News

RSS

Psychosocial interventions can reduce cancer patients' pain severity

Researchers at Moffitt Cancer Center, who teamed with colleagues at five universities around the United States, analyzed past studies of cancer-related pain reduction and found that psychosocial interventions can have a beneficial effect on cancer patients' pain severity. They also found that certain psychosocial interventions provide better pain management and are effective in reducing the degree to which pain related to cancer and its treatment interferes with patients' lives.

31 Jan 2012

MT2 gene mutations may increase risk of diabetes

Researchers in Lille and Paris demonstrated that mutations in the melatonin receptor gene (melatonin or the "hormone of darkness" induces sleep) lead to an almost sevenfold increase in the risk of developing diabetes.

31 Jan 2012

Researchers decipher genetic material of 48 pediatric glioblastomas

Glioblastomas grow extremely aggressively into healthy brain tissue and, moreover, are highly resistant to radiation therapy and chemotherapy. Therefore, they are regarded as the most malignant type of brain tumor. Currently available treatment methods are frequently not very effective against this type of cancer. Glioblastoma can affect people of all ages, but is less common in children than in adults.

31 Jan 2012

VPH's stroke center receives S. Mark Taper Foundation grant

The S. Mark Taper Foundation awarded a grant of $30,000 to Valley Presbyterian Hospital (VPH) for its Stroke Center, a state-of-the-art facility using the latest in telemedicine and diagnostic tools to ensure the best possible outcomes for its patients, Gustavo Valdespino, President and CEO of VPH, announced today.

31 Jan 2012

Alnylam receives U.S. patent allowance for LNP platform

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application number 12/813,448, covering the company's proprietary second generation lipid nanoparticle (LNP) platform, including the "MC3" lipid.

30 Jan 2012

For stroke prevention, large medical centers may have the edge

Despite advances in the diagnosis and treatment of unruptured brain aneurysms, outcomes have remained stagnant over the last 10 years. This can be explained by the dramatic proliferation of minimally invasive endoscopic coiling procedures at lower-volume community hospitals, where outcomes are inferior.

30 Jan 2012

Fewer getting screened for common cancers: CDC report

According to federal health officials last Thursday, the number of Americans being screened for colon, breast and cervical cancers still fall below national targets.

30 Jan 2012

Research advances understanding of hypoxic response

A new family of proteins which regulate the human body's 'hypoxic response' to low levels of oxygen has been discovered by scientists at Barts Cancer Institute at Queen Mary, University of London and The University of Nottingham.

30 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

FDA approves Medtronic DF4 High-Voltage Connector System for ICDs and CRT-Ds

Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.

From Medtronic 30 Jan 2012

Newly discovered molecular pathway may explain how AML develops

Researchers at UC Santa Barbara have discovered a molecular pathway that may explain how a particularly deadly form of cancer develops. The discovery may lead to new cancer therapies that reprogram cells instead of killing them. The findings are published in a recent paper in the Journal of Biological Chemistry.

30 Jan 2012

ASI's GenASIs for detection of chromosomal aberrations in bladder cancer receives FDA approval

Applied Spectral Imaging (ASI) announced today that ASI's GenASIs Scan & Analysis, SpotScan used for the detection of chromosomal aberrations in bladder cancer has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

30 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Covidien Solitaire FR Revascularization Device approved for investigational use

Covidien, a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved for investigational use in the Interventional Management of Stroke (IMS III) trial.

30 Jan 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

FDA approves Lannett's ANDA for Hydrochlorothiazide Capsules, 12.5 mg

Lannett Company, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg.

30 Jan 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012

MRI shows elevated BMI linked to greater extent and severity of degenerative disc disease

One of the largest studies to investigate lumbar spine disc degeneration found that adults who are overweight or obese were significantly more likely to have disc degeneration than those with a normal body mass index (BMI).

30 Jan 2012

Helios Berlin Buch acquires Mobetron for Intra-Operative Electron Radiation Therapy

IntraOp Medical Corporation today announced that Helios Berlin Buch became the fourth German hospital and the nineteenth European hospital to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

30 Jan 2012